Talphera (TLPH) Stock Price, News & Analysis

Company Overview

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Key Stats

• Today's Range: $0.83 to $0.90
• 50-Day Range: $0.72 to $0.91
• 52-Week Range: $0.38 to $1.57
• Volume: 406,526 shs
• Average Volume: 137,323 shs
• Market Capitalization: $43.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Talphera Stock Analysis - MarketRank™

Talphera scored higher than 80% of companies evaluated by MarketBeat, and ranked 118th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Talphera has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Talphera has a consensus price target of $3.00, representing about 254.3% upside from its current price of $0.85.

Amount of Analyst Coverage

Talphera has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Talphera is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Talphera is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Talphera has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.87% of the float of Talphera has been sold short.

Short Interest Ratio / Days to Cover

Talphera has a short interest ratio ("days to cover") of 6.75.

Change versus previous month

Short interest in Talphera has recently decreased by 9.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Talphera does not currently pay a dividend.

Dividend Growth

Talphera does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.90

News Sentiment

Talphera has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Talphera this week, compared to 2 articles on an average week.

Search Interest

18 people have searched for TLPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Talphera to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.4 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $125,853.00 in company stock, which represents 0.2864% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Talphera insiders have bought more of their company's stock than they have sold. Specifically, they have bought $125,853.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

3.50% of the stock of Talphera is held by insiders.

Percentage Held by Institutions

37.67% of the stock of Talphera is held by institutions.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 6/08/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLPH
• Previous Symbol: NASDAQ:TLPH
• CIK: 1427925
• Web: talphera.com
• Phone: 650-216-3500
• Fax: 650-216-6500
• Employees: 19
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Talphera: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +254.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.29 million
• Net Margins: N/A
• Pretax Margin: -1,425,300.00%
• Return on Equity: -92.98%
• Return on Assets: -53.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.30
• Quick Ratio: 5.30

Sales & Book Value

• Annual Sales: $30 thousand
• Price / Sales: 1,464.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 2.29

Miscellaneous

• Outstanding Shares: 51,900,000
• Free Float: 50,084,000
• Market Cap: $43.95 million
• Optionable: Optionable
• Beta: 0.76